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Since the FDA’s approval of tPA for the treatment of acute ischemic stroke 1, the search for
means to identify patients who may benefit from this treatment beyond the approved
therapeutic window has been actively pursued. One of the most successful examples is the
ECASS III (European Cooperative Acute Stroke Study III) trial 2, 3, which demonstrated
efficacy of tPA treatment could be extended from the original 3hrs to 4.5hrs from onset. In
addition, with an accumulating arsenal of mechanical clot retrieval devices promising to
achieve more effective reperfusion than IV-tPA4–6, it is likely that the therapeutic windows
for these retrieval devices will differ from that of IV-tPA. Different collateral flow patterns,
comorbidities, and intrinsic tissue vulnerabilities among individual patients further
complicate the use of a fixed therapeutic time-window for all patients and different
treatments. Therefore, insights into brain tissue viability at the time of presentation may aid
in the management of acute stroke.
Toward this end, imaging approaches have been actively sought to potentially provide a
signature for tissue viability 7. Specifically, the diffusion/perfusion mismatch (DPM)
concept has been widely advocated as a potential approach to depict the presence or absence
of ischemic “penumbra” 8–10. The underlying hypothesis is that lesions defined by abnormal
diffusion most likely reflect irreversible injury while regions defined by abnormal perfusion
represent critically hypoperfused tissue. The region of DPM with normal diffusion but
abnormal perfusion is, in theory, the region at risk of evolving to infarction if reperfusion-
promoting therapies are not administered. While the overall hypothesis of DPM is
straightforward and diffusion weighted images (DWI) and perfusion-weighted images (PWI)
are readily available, the means by which DWI and PWI lesions are defined vary widely,
leading to, potentially, inconsistent results among groups with the use of DPM to predict
outcomes. For example, the DEFUSE-2 investigators11 propose a set of criteria for defining
DPM, termed “target DPM”, based on observations of DWI lesion growth and clinical
outcome in patients undergoing intra-arterial (IA) therapy for acute hemispheric stroke.
However, the observations of the acute reversal of DWI lesions and the failure of all
diffusion lesions to evolve to infarction suggest that the presumption that all DWI-defined
lesions truly reflect the irreversibly damaged ischemic core may be invalid 12, 13. Similarly,
it has been difficult to define specific thresholds for PWI that differentiate tissue that is
mildly hypoperfused but not in danger of infarction from tissue that is critically
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hypoperfused and will go on to die quickly if not reperfused. Therefore, a more direct means
to assess tissue viability using imaging may improve our ability to stratify patients for
individualized treatment.
Positron emission tomography (PET)-measured cerebral metabolic rate of oxygen utilization
(CMRO2) is capable of discerning brain tissue viability in both transient and permanent
middle cerebral artery occlusion (MCAO) primate models 14. However, the need for an
onsite cyclotron as well as access to an arterial line for quantitative measures have largely
limited the clinical utility of PET, particularly for imaging acute stroke patients.
Alternatively, using blood oxygen level dependent (BOLD) contrast and a signal model
proposed by Yablonskiy and Haacke 15, our group has developed an MR-based approach for
obtaining quantitative measures of cerebral blood oxygen extraction fraction
(MR_OEF) 16–20. Extensive validation studies have been conducted, in animal models 19
and in human volunteers 16, 18. With animals exposed to different levels of gas challenges to
induce a physiologically relevant range of cerebral oxygen extraction, MR_OEF shows
highly accurate results when directly compared to blood samples taken from the internal
jugular vein19. In addition, normal volunteer studies have confirmed that MR measured OEF
values in humans under normal physiological conditions are consistent with that reported
using PET; OEF is decreased in response to hypercapnic challenge in humans which agrees
with the expected physiological response18, 20.
With the ability to non-invasively measure OEF using MRI, an index of cerebral metabolic
rate of oxygen utilization (MR_OMI) is derived as MR_OEF x cerebral blood flow
(CBF) 21–23 where CBF can be readily obtained using either the dynamic susceptibility
contrast and/or arterial spin labeling approaches. Although the intrinsic differences between
PET CMRO2 and MR_OMI prevent a direct comparison of absolute values, evidence
suggests that the MR_OMI is a physiological parameter closely related to PET measured
CMRO2, with all of the inherent advantages of using MRI rather than PET. Specifically,
MR_OMI reveals that the oxygen utilization in gray matter is two times higher than that in
the white matter, consistent with that reported in the PET literature21. Furthermore, with a
rat MCAO model, MR_OMI reveals spatiotemporal changes of oxygen metabolism during
acute ischemia consistent with PET studies in non-human primates and more importantly,
severe reductions of MR_OMI are highly predictive of final infarction19. Here, we report
our results on the utilization of MR_OMI in delineating the ischemic penumbra in acute
ischemic stroke patients. A total of 38 acute ischemic stroke patients were imaged at 3.0 hr
(tp1), 6.2 hr (tp2), and 1 month (tp3) after symptom onset. Dynamic susceptibility contrast
and asymmetry spin echo measured CBF and OEF, respectively. Some patients received
intravenous tPA, which was started prior to and continued during tp1 imaging without
delaying treatment. Images from the same subjects but acquired at different time points were
co-registered.
Fig 1 provides examples of MR_OMI illustrating its ability to provide information on
spatiotemporal dynamics of lesion progression in four representative clinical cases. Here we
compare MR_OMI with the widely used DWI/PWI approaches. Specifically, Fig 1a and Fig
1b show two patients, both with DWI/PWI matched lesions throughout tp1 and tp2. Based
on the notion of DPM, the presence of DWI/PWI matched lesions implies little salvageable
tissue at the time of imaging. Indeed, all three imaging approaches (DWI/PWI/MR_OMI)
exhibit similar information showing a stable lesion in Fig. 1a, which is highly consistent
with the final infarction. However, although DWI and PWI again provide a similar
representation of an ischemic lesion at both tp1 and tp2 in Fig. 1b, MR_OMI reveals a
continuous worsening of the ischemic lesion from tp1 to tp2 (circles), suggesting that viable
tissue may exist at tp1 but it evolves to final infarction since reperfusion was not
accomplished. In contrast to the first two examples, Fig. 1c and Fig. 1d show two other
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patients, both with DPM lesions. As suggested by the concept of DPM, early reperfusion of
the mismatched region may salvage reversibly injured tissue whereas no reperfusion would
result in infarction of the mismatched region. Consistent with this premise, the reperfused
region (Fig. 1c, arrow) did not evolve into infarction and again DWI/PWI/MR_OMI provide
similar information characterizing the ischemic lesion and are consistent with the final
lesion. However, although early reperfusion is not observed in Fig. 1d, MR_OMI shows a
rather stable lesion during both tp1 and tp2, which is more consistent with the final lesion
than that provided by DWI/PWI. Together, although qualitatively, the above examples
suggest that the MR_OMI may provide more underlying metabolic insights and more
faithfully depict tissue viability than that of DPM.
To further determine the effectiveness of MR_OMI in delineating the ischemic penumbra, a
quantitative study was conducted. Our analysis approach postulates an ideal case in which
two MR_OMI threshold values could be obtained to bracket the ischemic penumbra: One
threshold would distinguish ischemic core from penumbra (Thr1); a second threshold would
distinguish penumbra from oligemia (Thr2) such that core, penumbra, and oligemia are
defined as MR_OMIcore < Thr1, Thr1 < MR_OMIpenumbra < Thr2, and MR_OMIoligemia >
Thr2. With this assumption, voxels classified as core should all die (100% infarct probability
(IP)) while voxels defined as oligemia should all survive (IP=0%), both independent of
whether or not reperfusion occurs. In contrast, the final fate of voxels in the ischemic
penumbra area should vary depending on the presence or absence of reperfusion; if
reperfusion is achieved (similar to Fig. 1c), all reperfused penumbra should survive (IP=0%)
whereas all non-reperfused penumbra should die (IP=100%)24. To this end, normalized
MR_OMI (nMR_OMI) within gray and white matter was obtained by separately
normalizing their MR_OMI to the median MR_OMI of the contralateral hemisphere gray
and white matter, respectively. In addition, prolonged MTT (pMTT), defined as the
difference of MTT in the ipsilateral hemisphere from the median MTT of the contralateral
hemisphere, was used to determine the presence or absence of reperfusion. Specifically, a
voxel with pMTT at tp1 >4 sec and pMTT at tp2 < 4sec was considered to have been
hypoperfused then reperfused. Subsequently, a search method was used to determine an
optimal pair of Thr1 and Thr2 for each patient by minimizing the “average prediction error
(APE)”, defined as the average differences for each tissue group’s actual IP from the ideal
IP (Table). The predictive abilities of the thresholds were tested in the same cohort using
“leave-one-out” cross-validation, and the APE averaged across the population. The core/
penumbra OMI threshold and the penumbra/oligemia OMI threshold ranged from 0.21–0.22
and 0.41–0.43 in individual patients, respectively. The median IP’s [IQR] for the 4 tissue
groups are shown (Table). The population averaged APE was 15% [5%, 24%]. Our results
show the robustness of the MR_OMI in predicting the final fate of ischemic tissue. 91.6% of
the core evolved to infarction while only 4.5% of oligemic tissue was infarcted. More
importantly, MR_OMI also demonstrated its ability to delineate penumbra, by predicting
reperfusion-dependent tissue fate: IP=6.8% with reperfusion and IP=73.6% without
reperfusion. These findings support the predictive value of MR_OMI. Nevertheless,
definitive conclusions regarding the true clinical utility of MR_OMI will need to be
evaluated with a prospective study using clinical outcomes.
In summary, we have provided evidence for the ability of MR_OMI to delineate the
ischemic penumbra. The validity of this tissue categorization is revealed by its ability to
predict final tissue fate in the presence or absence of reperfusion with a low error rate. While
these findings are promising, a larger multi-site prospective study to systematically evaluate
the clinical utility of MR_OMI in acute ischemic stroke patients is needed. If these results
are validated in a larger study, MR-OMI may provide a physiological alternative to our
current time-based therapeutic time-window for identifying patients for acute therapeutic
interventions.
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Four examples of acute lesion evolution characterized by DWI, PWI and MR_OMI are
provided. Specifically, a and b show two patients with DWI/PWI matched lesions
throughout both tp1 and tp2 whereas c and d provide two examples of DPM lesions,
respectively. Patient shown in a received tPA at 2:09hrs and tp1 and 2 imaging at 2:40hrs
and 6:20hrs from onset, respectively. Patient in b did not receive tPA due to secondary
increase of BP and seizure. The time of imaging for tp1 and tp2 was 4:30hrs and 6:45hrs
from onset, respectively. Please note that the FLAIR of this patient was acquired 72hrs after
onset, showing edema and the resulted midline shift and thus may not represent the true
extend of final infarction. Patient in c received tPA at 1:37hrs and time of imaging at 1:58hrs
and 6:05hrs for tp1 and tp2 from onset, respectively. Finally, d shows a patient who received
tPA at 1:19hrs and imaged at 2:10hrs and 6:28hrs after onset, respectively.
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TABLE
Reperfusion Status Core Penumbra Oligemia APE†
Non-reperfused
IP = 91.6% [76%, 97%]
IP = 73.6% [55%, 96%]
IP = 4.5% [2.9%, 13%] 15% [5%, 24%]
Reperfused IP = 6.8% [3.1%, 42%]
†
Average Prediction Error (APE) = [(100% − IPcore) + (100% − IPpenumbra_non-reperfused) + (IPpenumbra_reperfused − 0%) +
(IPoligemia − 0%)] / 4
Stroke. Author manuscript; available in PMC 2014 January 19.
